ES2392489T3 - Dicarbazoles y procedimientos de uso - Google Patents

Dicarbazoles y procedimientos de uso Download PDF

Info

Publication number
ES2392489T3
ES2392489T3 ES09762885T ES09762885T ES2392489T3 ES 2392489 T3 ES2392489 T3 ES 2392489T3 ES 09762885 T ES09762885 T ES 09762885T ES 09762885 T ES09762885 T ES 09762885T ES 2392489 T3 ES2392489 T3 ES 2392489T3
Authority
ES
Spain
Prior art keywords
alkyl
cr14r15
groups
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09762885T
Other languages
English (en)
Spanish (es)
Inventor
Hazel Joan Dyke
Emanuela Gancia
Lewis J. Gazzard
Simon Charles Goodacre
Joseph P. Lyssikatos
Calum Macleod
Karen Williams
Huifen Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2392489T3 publication Critical patent/ES2392489T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09762885T 2008-06-11 2009-06-10 Dicarbazoles y procedimientos de uso Active ES2392489T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6075008P 2008-06-11 2008-06-11
US60750P 2008-06-11
US14800409P 2009-01-28 2009-01-28
US148004P 2009-01-28
PCT/US2009/003481 WO2009151589A1 (en) 2008-06-11 2009-06-10 Diazacarbazoles and methods of use

Publications (1)

Publication Number Publication Date
ES2392489T3 true ES2392489T3 (es) 2012-12-11

Family

ID=41066268

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09762885T Active ES2392489T3 (es) 2008-06-11 2009-06-10 Dicarbazoles y procedimientos de uso

Country Status (12)

Country Link
US (1) US20110124654A1 (enExample)
EP (1) EP2324024B1 (enExample)
JP (2) JP5677945B2 (enExample)
KR (2) KR20110015699A (enExample)
CN (1) CN102119162B (enExample)
AU (1) AU2009258115B2 (enExample)
BR (1) BRPI0909957A2 (enExample)
CA (1) CA2726114A1 (enExample)
ES (1) ES2392489T3 (enExample)
IL (1) IL209548A (enExample)
MX (1) MX2010013606A (enExample)
WO (1) WO2009151589A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2726114A1 (en) * 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles and methods of use
CN108721284A (zh) 2010-11-16 2018-11-02 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
RU2635359C2 (ru) * 2012-04-23 2017-11-13 Дженентек Инк. Промежуточные химические соединения и способы получения соединений
EP2948438A4 (en) * 2013-01-23 2016-10-05 Univ Chicago METHOD AND COMPOSITIONS FOR INHIBITING THE HUMAN COPPER TRAFFICKING PROTEIN ATOX1 AND CCS
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
AU2014333996B2 (en) 2013-10-08 2018-03-15 F. Hoffmann-La Roche Ag Diazacarbazole derivatives as tau-pet-ligands
JP6840931B2 (ja) * 2015-03-09 2021-03-10 東ソー株式会社 縮環芳香族化合物の製造方法
US20170067946A1 (en) * 2015-06-08 2017-03-09 Zac WHEELER Monitoring system with low power usage
CN109789143A (zh) 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
WO2018046428A1 (en) 2016-09-09 2018-03-15 F. Hoffmann-La Roche Ag Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
JP7853532B2 (ja) 2020-05-19 2026-04-30 ファーマコスモス ホールディング エー／エス 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物
CN115572282B (zh) * 2021-07-05 2024-07-09 华东理工大学 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
CA2402549A1 (en) * 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
BRPI0407544A (pt) * 2003-02-17 2006-02-14 Pharmacia Italia Spa derivados de pirazol tetracìclicos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas que os compreendem
AR049300A1 (es) * 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
CA2726114A1 (en) * 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles and methods of use

Also Published As

Publication number Publication date
IL209548A0 (en) 2011-01-31
MX2010013606A (es) 2010-12-21
KR101764556B1 (ko) 2017-08-02
JP2014196309A (ja) 2014-10-16
CN102119162A (zh) 2011-07-06
IL209548A (en) 2014-03-31
KR20110015699A (ko) 2011-02-16
KR20160074680A (ko) 2016-06-28
CA2726114A1 (en) 2009-12-17
BRPI0909957A2 (pt) 2016-04-19
EP2324024A1 (en) 2011-05-25
US20110124654A1 (en) 2011-05-26
AU2009258115B2 (en) 2015-01-29
CN102119162B (zh) 2014-10-08
AU2009258115A2 (en) 2011-05-12
WO2009151589A1 (en) 2009-12-17
JP2011522888A (ja) 2011-08-04
JP5677945B2 (ja) 2015-02-25
AU2009258115A1 (en) 2009-12-17
EP2324024B1 (en) 2012-09-26

Similar Documents

Publication Publication Date Title
EP2324024B1 (en) Diazacarbazoles and methods of use
ES2399774T3 (es) Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso
AU2009258124C1 (en) Diazacarbazoles and methods of use
ES2392488T3 (es) Compuestos inhibidores de PI3K de tipo pirazolopiridina y sus procedimientos de uso
EP2164850B1 (en) N-substituted azaindoles and methods of use
CA2698753A1 (en) Pyrazolo-pyridines as tyrosine kinase inhibitors
CA2782213A1 (en) 1,7-diazacarbazoles and their use in the treatment of cancer
AU2014331049B2 (en) Conformationally restricted PI3K and mTOR inhibitors
BR112012011147A2 (pt) Composto, composição farmacêutica e uso de um composto.
JP2015504876A (ja) セリン／トレオニンキナーゼ阻害剤としての２，４−ジアミン−ピリミジン誘導体
EP2300457B1 (en) Substituted pyrroles and methods of use
US20150368244A1 (en) Diazacarbazoles and methods of use
HK40091719B (en) Substituted fused heterocyclic compound, and preparation method therefor and use thereof
HK40091719A (en) Substituted fused heterocyclic compound, and preparation method therefor and use thereof
WO2023116594A1 (zh) 取代的稠杂环化合物及其制备方法与应用